The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zadionchenko E.V.

Evdokimov Moscow State University of Medicine and Dentistry

Klyuchnikova D.E.

Evdokimov Moscow State University of Medicine and Dentistry

Zvezdina I.V.

Evdokimov Moscow State University of Medicine and Dentistry

Denisova E.V.

Far-Eastern State Medical University

Special aspects of prurigo nodularis diagnosis and treatment

Authors:

Zadionchenko E.V., Klyuchnikova D.E., Zvezdina I.V., Denisova E.V.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2022;21(5): 656‑662

DOI: 10.17116/klinderma202221051656

Views: 12604

Downloaded: 207

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Zadionchenko EV, Klyuchnikova DE, Zvezdina IV, Denisova EV. Special aspects of prurigo nodularis diagnosis and treatment. Russian Journal of Clinical Dermatology and Venereology. 2022;21(5):656‑662. (In Russ.)
https://doi.org/10.17116/klinderma202221051656

 
МСФ на ЯМ
Close metadata

Prurigo nodularis is a rare multifactorial neuroallergic dermatosis characterized by a chronic course and a significant reduction in patients’ quality of life. A severe nodular rash and virtually unceasing itching significantly affect the patient’s appearance and aggravates their psychological state. Treatment is challenging since current therapeutic agents are not always effective due to the prurigo nodularis pathogenesis features and the need for long therapy courses using systemic and topical medications and physiotherapeutic treatment. A review of the literature related to prurigo nodularis pathogenesis was carried out; the differential diagnostics with other dermatoses with a similar clinical presentation and treatment with systemic and topical agents were considered. The authors describe a clinical case of prurigo nodularis with a torpid course from their practice.

Keywords:

prurigo nodularis
prurigo
allergic dermatoses
itching
neuroticism

Authors:

Zadionchenko E.V.

Evdokimov Moscow State University of Medicine and Dentistry

Klyuchnikova D.E.

Evdokimov Moscow State University of Medicine and Dentistry

Zvezdina I.V.

Evdokimov Moscow State University of Medicine and Dentistry

Denisova E.V.

Far-Eastern State Medical University

Received:

11.01.2022

Accepted:

01.09.2022

List of references:

  1. Pereira MP, Steinke S, Zeidler C, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J European Academy of Dermatology & Venereology. 2018;7:1059-1065. https://doi.org/10.1111/jdv.14570
  2. Russian Society of Dermatovenerologists and Cosmetologists. Clinical Recommendations. Prurigo. M. 2020:6,8. (In Russ.).
  3. Jørgensen KM, Egeberg A, Gislason GH, et al. Anxiety, depression and suicide in patients with prurigo nodularis. J European Academy of Dermatology & Venereology. 2016;31(2):106-107.  https://doi.org/10.1111/jdv.13827
  4. Huang AH, Williams KA, Kwatra SG. Prurigo nodularis: Epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559-1565. https://doi.org/10.1016/j.jaad.2020.04.183
  5. Prurigo Nodularis Epidemiology Forecast Report 2017-2030: Focus on United States, Germany, Spain, Italy, France, and United Kingdom, and Japan. Research And Markets. February 16, 2021. Accessed Dec 6, 2021. https://www.researchandmarkets.com/reports/5067406/prurigo-nodularis-epidemiology-forecast-to-2030
  6. Wyss-Chodat F. Die Behandlung pruriginöser Erkrankungen mit synthetischen Antihistaminika. Ther Umsch. 1962;19:379-382. (In German).
  7. Johansson O, Liang Y, Marcusson JA, Reimert CM. Eosinophil cationic protein- and eosinophil-derived neurotoxin/eosinophil protein X-immunoreactive eosinophils in prurigo nodularis. Arch Dermatol Res. 2000;292(8): 371-378.  https://doi.org/10.1007/s004030000142
  8. Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol. 2011;165(5): 990-996.  https://doi.org/10.1111/j.1365-2133.2011.10498.x
  9. Sonkoly E, Muller A, Lauerma AI, et al. IL-31: A new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006; 117(2):411-417.  https://doi.org/10.1016/j.jaci.2005.10.033
  10. Iking A, Grundmann S, Chatzigeorgakidis E, et al. Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad Dermatol Venereol. 2013;27(5):550-557.  https://doi.org/10.1111/j.1468-3083.2012.04481.x
  11. Johansson O, Liang Y, Emtestam L. Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin — an exploration of the cause of neurohyperplasia. Arch Dermatol Res. 2002;293(12): 614-619.  https://doi.org/10.1007/s00403-001-0285-8
  12. Liang Y, Marcusson JA, Jacobi HH, et al. Histamine-containing mast cells and their relationship to NGFr-immunoreactive nerves in prurigo nodularis: a reappraisal. J Cutan Pathol. 1998;25(4):189-198.  https://doi.org/10.1111/j.1600-0560.1998.tb01718.x
  13. Liang Y, Jacobi HH, Reimert CM, et al. CGRP-immunoreactive nerves in prurigo nodularis — an exploration of neurogenic inflammation. J Cutan Pathol. 2000; 27(7):359-366.  https://doi.org/10.1034/j.1600-0560.2000.027007359.x
  14. Schuhknecht B, Marziniak M, Wissel A, et al. Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy. Br J Dermatol. 2011;165(1):85-91.  https://doi.org/10.1111/j.1365-2133.2011.10306.x
  15. Zeidler C, Ständer S. The pathogenesis of Prurigo nodularis — ‘Super-Itch’ in exploration. European Journal of Pain. 2015;20(1):37-40.  https://doi.org/10.1002/ejp.767
  16. Haas S, Capellino S, Quan Phan N, et al. Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis. Journal of Dermatological Science. 2010; 58(3):193-197.  https://doi.org/10.1016/j.jdermsci.2010.03.020
  17. Kwatra SG. Breaking the Itch — Scratch Cycle in Prurigo Nodularis. The New England Journal of Medicine. 2020;382(8):757-758.  https://doi.org/10.1056/nejme1916733
  18. Francesco Stefanini G, Resta F, Marsigli L, et al. Prurigo nodularis (Hyde’s prurigo) disclosing celiac disease. Hepatogastroenterology Journal. 1999; 46(28):2281-2284. PMID: 10521982.
  19. Winhoven SM, Gawkrodger DJ. Nodular prurigo: metabolic diseases are a common association. Clinical and Experimental Dermatology. 2007;32(2): 224-225.  https://doi.org/10.1111/j.1365-2230.2006.02310.x
  20. Yousaf M, Gwillim EC, Lee H, et al. The association between prurigo nodularis and mental health comorbidities: A systematic review and meta-analysis. Journal of the American Academy of Dermatology. 2020;83(6):AB38. https://doi.org/10.1016/j.jaad.2020.06.240
  21. Mettang T, Vonend A, Raap U. Prurigo nodularis bei Dermatosen und systemischen Erkrankungen. Der Hautarzt. 2014;65(8):697-703.  https://doi.org/10.1007/s00105-014-2755-x
  22. Larson VA, Tang O, Ständer S, et al. Association between prurigo nodularis and malignancy in middle-aged adults. Journal of Investigative Dermatology, 2019;139(5):41.  https://doi.org/10.1016/j.jid.2019.03.314
  23. Kuno Y, SatoK, Hasegawa K, Tsuji T, et al. A case of actinic prurigo showing hypersensitivity of skin fibroblaststo ultraviolet A (UVA). Photodermatology, Photoimmunology & Photomedicine. 2000;16(1):38-41.  https://doi.org/10.1034/j.1600-0781.2000.160110.x
  24. Slesarenko NA, Utz SR, Bakulev AL, et al. Clinical polymorphism of lichen ruber planus (review). Saratov Journal of Medical Scientific Research. 2017; 13(3):652-661. (In Russ.).
  25. Weston G, Payette M. Update on lichen planus and its clinical variants. International Journal of Women’s Dermatology. 2015;1(3):140-149.  https://doi.org/10.1016/j.ijwd.2015.04.001
  26. Kisina VI, Dvoryankova EV, Petunina VV, Sapozhnikova YuA. Modern ideas about the problem of diagnosis and treatment of scabies. Almanac of Clinical Medicine. 2007;15:180-187. (In Russ.).
  27. Utz SR, Zavialov AI, Marchenko VM. Clinical and epidemiological signs of scabies and modern methods of diagnostics and treatment (review). Saratov Journal of Medical Scientific Research. 2011;7(3):636-641. (In Russ.).
  28. Katina MA, Lesnichaya OV. A case of pseudolymphoma of the skin (lymphoid hyperplasia of the skin) on the background of untreated scabies. Bulletin of the VSMU. 2018;17(3):76-83. (In Russ.). https://doi.org/10.22263/2312-4156.2018.3.76
  29. Tlish MM, Sycheva NL, Shavilova ME. Dermatological manifestations of amyloidosis. Clinical Medicine. 2019;97(1):59-64. (In Russ.).
  30. Zaborova VA, Grusha YaO, Sarkisova IA, et al. Amyloid disease (skin and systemic manifestations). Russian Journal of Skin and Venereal Diseases. 2007;6:8-13. (In Russ.).
  31. Kwon CD, Khanna R, Williams KA, Kwatra MM, Kwatra SG. Diagnostic Workup and Evaluation of Patients with Prurigo Nodularis. Medicines (Basel, Switzerland). 2019;6(4):97.  https://doi.org/10.3390/medicines6040097
  32. Vijaya B, Dalal BS, Sunila, Manjunath GV. Primary cutaneous amyloidosis: A clinico-pathological study with emphasis on polarized microscopy. Indian Journal of Pathology and Microbiology. 2012;55(2):170.  https://doi.org/10.4103/0377-4929.97853
  33. Katayama I, Miyazaki Y, Nishioka K. Topical vitamin D3 (tacalcitol) for steroid-resistant prurigo. The British Journal of Dermatology. 1996;135(2):237-240. 
  34. Ryan S. Nodular prurigo: An overview of diagnosis and management. Dermatological Nursing. 2017;16(4):18-21. 
  35. Shintani T, Ohata C, Koga H, et al. Combination therapy of fexofenadine and montelukast is effective in prurigo nodularis and pemphigoid nodularis. Dermatol Ther. 2014;27(3):135-139.  https://doi.org/10.1111/dth.12094
  36. Gencoglan G, Inanir I, Gunduz K. Therapeutic hotline: Treatment of prurigo nodularis and lichen simplex chronicus with gabapentin. Dermatol Ther. 2010;23(2):194-198.  https://doi.org/10.1111/j.1529-8019.2010.01314.x
  37. Mazza M, Guerriero G, Marano G, Janiri L, Bria P, Mazza S. Treatment of prurigo nodularis with pregabalin. J Clin Pharm Ther. 2013;38(1):16-18.  https://doi.org/10.1111/jcpt.12005
  38. Chan S, Reddy V, Myers B, et al. High-dose doxepin for the treatment of chronic, intractable scalp pruritu. JAAD Case Reports. 2020;8:71-73.  https://doi.org/10.1016/j.jdcr.2020.12.017
  39. Mullins TB, Sharma P, Riley CA, Sonthalia S. Prurigo Nodularis. 2021 Sept 14. In: StatPearls [Internet]. Treasure Island (FL): Stat Pearls Publishing. 2021. PMID: 29083653.
  40. Tamagawa-Mineoka R, Katoh N, Ueda E, Kishimoto S. Narrow-band ultraviolet B phototherapy in patients with recalcitrant nodular prurigo. Journal of Dermatology. 2007;34(10):691-695. 
  41. Ständer S, Yosipovitch G, Legat FJ, et al. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. The New England Journal of Medicine. 2020;382(8): 706-716.  https://doi.org/10.1056/NEJMoa1908316
  42. Napolitano M, Fabbrocini G, Scalvenzi M, et al. Effectiveness of Dupilumab for the Treatment of Generalized Prurigo Nodularis Phenotype of Adult Atopic Dermatitis. Dermatitis: contact, atopic, occupational, drug. Dermatitis. 2020;31(1):81-84.  https://doi.org/10.1097/DER.0000000000000517
  43. Wiznia LE, Callahan SW, Cohen DE, Orlow SJ, et al. Rapid improvement of prurigo nodularis with cyclosporine treatment. Journal of the American Academy of Dermatology. 2018;78(6):1209-1211. https://doi.org/10.1016/j.jaad.2018.02.024
  44. Klejtman T, Beylot-Barry M, Joly P, et al. Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases. Journal of the European Academy of Dermatology and Venereology. 2018;32(3):437-440. 
  45. Tsianakas A, Zeidler C, Riepe C, et al. Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU). Acta Derm Venereol. 2019;99(4):379-385.  https://doi.org/10.2340/00015555-3120
  46. Chiou AS, Choi S, Barriga M, et al. Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial. J Am Acad Dermatol. 2020;82(6):1415-1421. https://doi.org/10.1016/j.jaad.2019.09.014

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.